Compared side by side
Pemvidutide vs efinopegdutide: how they differ
The short answer
Both are weekly GLP-1 and glucagon dual agonists now developed mainly for liver disease: pemvidutide, from Altimmune, is balanced 1:1 between the two receptors, and efinopegdutide, now with Merck, is tuned about 2 to 1 toward GLP-1. Neither is approved; pemvidutide’s phase 3 trial began in 2026. In people with fatty liver, pemvidutide cut liver fat by about half or more within 12 to 24 weeks, and efinopegdutide by about 73% in a 24-week trial.
Side by side
| Compared | Pemvidutide | Efinopegdutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | ALT-801 | MK-6024, JNJ-64565111, Efino |
| What it is | An investigational once-weekly GLP-1 and glucagon dual agonist from Altimmune, built for a gentler start: its two lower doses were given from the first injection without a dose ramp. | A once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease. |
| How it works | Once-weekly GLP-1 and glucagon dual agonist from Altimmune, balanced 1:1 between the two receptors. Its EuPort domain binds albumin to slow its clearance for weekly dosing and, the company says, slows its entry into the blood, which it links to its tolerability. The GLP-1 arm curbs appetite; the glucagon arm acts directly on the liver, where it raises fat burning and curbs fat-making, and its developer now runs it mainly for liver disease. Investigational: not approved anywhere. | Once-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck. |
| Commonly reported | Very little yet; it is rarely run outside trials. | GI side effects during step-ups, and weight loss too. Not approved anywhere. |
| Studied range | Research range: 1.2–2.4 mg, starting dose 1.2 mg. Studied in research — not a recommendation. | Research range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | Not published: built for weekly dosing (its EuPort domain binds albumin to slow clearance), but no human half-life has been released | Not reported in an open human PK source; dosed once weekly in all its trials |
| Route | SubQ injection | SubQ injection |
| Typical run | Continuous weekly dosing in all its trials (12 to 48 weeks); no data on stopping or cycling. | Used continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it. |
| Evidence | Moderate: animal studies + some human data | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, constipation, diarrhea | Nausea, vomiting, diarrhea |
- Category
- PemvidutideMetabolic & GLP-1
- EfinopegdutideMetabolic & GLP-1
- Also known as
- PemvidutideALT-801
- EfinopegdutideMK-6024, JNJ-64565111, Efino
- What it is
- PemvidutideAn investigational once-weekly GLP-1 and glucagon dual agonist from Altimmune, built for a gentler start: its two lower doses were given from the first injection without a dose ramp.
- EfinopegdutideA once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease.
- How it works
- PemvidutideOnce-weekly GLP-1 and glucagon dual agonist from Altimmune, balanced 1:1 between the two receptors. Its EuPort domain binds albumin to slow its clearance for weekly dosing and, the company says, slows its entry into the blood, which it links to its tolerability. The GLP-1 arm curbs appetite; the glucagon arm acts directly on the liver, where it raises fat burning and curbs fat-making, and its developer now runs it mainly for liver disease. Investigational: not approved anywhere.
- EfinopegdutideOnce-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck.
- Commonly reported
- PemvidutideVery little yet; it is rarely run outside trials.
- EfinopegdutideGI side effects during step-ups, and weight loss too. Not approved anywhere.
- Studied range
- PemvidutideResearch range: 1.2–2.4 mg, starting dose 1.2 mg. Studied in research — not a recommendation.
- EfinopegdutideResearch range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation.
- How often
- PemvidutideWeekly
- EfinopegdutideWeekly
- Half-life
- PemvidutideNot published: built for weekly dosing (its EuPort domain binds albumin to slow clearance), but no human half-life has been released
- EfinopegdutideNot reported in an open human PK source; dosed once weekly in all its trials
- Route
- PemvidutideSubQ injection
- EfinopegdutideSubQ injection
- Typical run
- PemvidutideContinuous weekly dosing in all its trials (12 to 48 weeks); no data on stopping or cycling.
- EfinopegdutideUsed continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it.
- Evidence
- PemvidutideModerate: animal studies + some human data
- EfinopegdutideModerate: animal studies + some human data
- Common side effects
- PemvidutideNausea, vomiting, constipation, diarrhea
- EfinopegdutideNausea, vomiting, diarrhea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Pemvidutide
- Day 1–84 · 1.2 mg No ramp at this dose
- Day 1–84 · 1.8 mg Most side effects come early
- Day 1–112 · 2.4 mg The top dose, after a short ramp
- Day 57–168 Liver fat drops faster than weight
- Day 169–336 Most of the loss is fat
Efinopegdutide
- Day 1–28 · 2 mg A gentle first month
- Day 29–364 · 4 mg Four milligrams
- Day 57–364 · 7 mg The dose the trial favoured
- Day 57–364 Weight comes down too
- Day 85–364 · 10 mg Ten milligrams: more side effects, not more benefit
Questions people ask
How long do pemvidutide and efinopegdutide last?
The half-life of pemvidutide is not published: built for weekly dosing (its EuPort domain binds albumin to slow clearance), but no human half-life has been released. The half-life of efinopegdutide is not reported in an open human PK source; dosed once weekly in all its trials.
How often are pemvidutide and efinopegdutide taken?
Pemvidutide: weekly. Route: SubQ injection. Efinopegdutide: weekly. Route: SubQ injection.
How are pemvidutide and efinopegdutide dosed in research?
The research range for pemvidutide is 1.2–2.4 mg, with a 1.2 mg starting dose. The research range for efinopegdutide is 4–10 mg, with a 2 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of pemvidutide and efinopegdutide?
For pemvidutide, the library lists: nausea, vomiting, constipation, diarrhea. For efinopegdutide: nausea, vomiting, diarrhea.